Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- Check4 days agoChange DetectedFooter revision updated from v3.5.4 to v3.5.5, indicating a new version of the page. No substantive content, including the study details or eligibility criteria, was changed.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, signaling a new release of the page content.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page’s revision label was updated from v3.5.2 to v3.5.3, indicating a version/release change to the ClinicalTrials.gov site interface rather than a modification to the study content.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision updated from v3.4.2 to v3.5.0 on the page.SummaryDifference0.1%

- Check119 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2, a routine system update with no user-facing changes to content or studies.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.